Boehringer Files Pradaxa Antidote, Could Lead To Reversible Novel Anticoagulant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.